logo
Plus   Neg
Share
Email

Fulcrum Therapeutics: FDA Grants Orphan Drug Designation To Losmapimod

Fulcrum Therapeutics, Inc. (FULC) announced the FDA has granted Orphan Drug Designation to losmapimod, a selective p38a/ß mitogen activated protein kinase inhibitor for the treatment of facioscapulohumeral muscular dystrophy. The company is currently conducting Phase 2 trials investigating the safety, tolerability, and efficacy of losmapimod to treat the root cause of facioscapulohumeral muscular dystrophy.

The company also announced the issuance of a U.S. patent with claims covering the use of other p38 kinase inhibitors for the treatment of facioscapulohumeral muscular dystrophy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT